IMcoMET

IMcoMET is a Rotterdam-based medical technology company that develops microneedle-based devices for minimally invasive access to dermal interstitial fluid. Its core innovation, the M-Duo Technology, uses a dual-needle system to inject and retrieve carrier fluid directly from the dermis, allowing for the sampling of soluble biomarkers such as proteins and metabolites without the need for traditional tissue biopsies. By utilizing 3D-printed, biocompatible microneedles that target the dermis while avoiding blood vessels and nerves, the company provides a localized and potentially continuous method to study skin biology. Beyond its diagnostic patch, IMcoMET produces specialized pre-clinical laboratory tools, including the Porcupine for 3D tissue culture study, an automated animal sampling device, and the ToTEM platform for 3D tissue mapping.

These technologies are designed to facilitate more feasible translational research and clinical trials by reducing the procedural burden and physical trauma associated with conventional skin sampling. By providing direct access to the local skin microenvironment, the company enables researchers and pharmaceutical partners to monitor disease activity and therapeutic response with higher precision. IMcoMET is actively pursuing applications in dermatology, inflammatory skin conditions, and oncology, including investigating ways to inhibit tumor growth through the targeted removal of immune-suppressive signals. The company is currently working toward regulatory approval for its diagnostic and therapeutic platforms, collaborating with academic and commercial partners to advance biomarker discovery and personalized medicine.